Practice network-based care management for patients with type 2 diabetes and multiple comorbidities (GEDIMAplus): study protocol for a randomized controlled trial by Bozorgmehr, Kayvan  et al.
TRIALS
Bozorgmehr et al. Trials 2014, 15:243
http://www.trialsjournal.com/content/15/1/243STUDY PROTOCOL Open AccessPractice network-based care management for
patients with type 2 diabetes and multiple
comorbidities (GEDIMAplus): study protocol for a
randomized controlled trial
Kayvan Bozorgmehr1*, Joachim Szecsenyi1, Dominik Ose1, Werner Besier2, Manfred Mayer2, Johannes Krisam3,
Christian O Jacke4, Hans-Joachim Salize4, Ralf Brandner5, Sandra Schmitt5, Marion Kiel1, Martina Kamradt1
and Tobias Freund1Abstract
Background: Care management interventions in the German health-care system have been evaluated with promising
results, but further research is necessary to explore their full potential in the context of multi-morbidity. Our aim in this
trial is to assess the efficacy of a primary care practice network–based care management intervention in improving
self-care behaviour among patients with type 2 diabetes mellitus and multiple co-occurring chronic conditions.
Methods/Design: The study is designed as a prospective, 18-month, multicentre, investigator-blinded, two-arm,
open-label, individual-level, randomized parallel-group superiority trial. We will enrol 582 patients with type 2 diabetes
mellitus and at least two severe chronic conditions and one informal caregiver per patient. Data will be collected at
baseline (T0), at the primary endpoint after 9 months (T1) and at follow-up after 18 months (T2). The primary outcome
will be the differences between the intervention and control groups in changes of diabetes-related self-care behaviours
from baseline to T1 using a German version of the revised Summary of Diabetes Self-Care Activities (SDSCA-G). The
secondary outcomes will be the differences between the intervention and control groups in: changes in scores on the
SDSCA-G subscales, glycosylated haemoglobin A level, health-related quality of life, self-efficacy, differences in (severe)
symptomatic hypoglycaemia, cost-effectiveness and financial family burden. The intervention will be delivered by
trained health-care assistants as an add-on to usual care and will consist of three main elements: (1) three home visits,
including structured assessment of medical and social needs; (2) 24 structured telephone monitoring contacts; and
(3) self-monitoring of blood glucose levels after T1 in 3-month intervals. The control group will receive usual care. The
confirmatory primary analysis will be performed following the intention-to-treat (ITT) principle. The efficacy of the
intervention will be quantified using two-level linear regression stratified by type of medical treatment adjusted for
baseline values on the SDSCA-G. Secondary analyses will be performed according to the ITT principle. In health
economic evaluations, we will estimate the incremental cost-effectiveness ratios.
Discussion: We hope that the results of this study will provide insights into the efficacy of practice network–based
care management among patients with complex health-care needs.
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The increasing prevalence of multiple, co-occurring chro-
nic conditions constitutes a burden for contemporary
health systems internationally [1] as well as in Germany
[2]. Multi-morbidity is associated with worse health out-
comes, more complex clinical management and increased
health-care costs [3]. Several suggestions have been made
regarding taking up the challenge of addressing this pro-
blem by reorganizing the delivery of chronic illness care
[4,5]. On the basis of these concepts, care management in-
terventions focusing on patients with multiple chronic
conditions have been developed and evaluated [6]. Care
management has been defined as ‘a set of activities
designed to assist patients and their support systems in
managing medical conditions and related psychosocial
problems more effectively, with the aim of improving
patients’ health status and reducing the need for medical
services’ [7]. These interventions share four core elements
[8]: (1) comprehensive assessment of patients’ medical and
nonmedical needs and resources, (2) implementation and
monitoring of individualized, evidence-based care plans,
(3) coordination of services between providers of medical
and social care and (4) enhancement of the self-manage-
ment capabilities of patients and caregivers.
In the context of type 2 diabetes mellitus, the concept of
‘self-care’ (a synonym for self-management) is playing an
increasingly important role in preventing complications
and coping with the consequences of the condition [7].
Relevant interrelated self-care dimensions for patients
with type 2 diabetes include adaptations of diet, exercise,
self-monitoring of blood glucose (SMBG), foot care,
medication adherence and smoking [9]. Diabetes typically
occurs with or has other chronic diseases as conse-
quences. Discordant comorbidities, such as depression
[10], constitute an additional challenge for patients with
diabetes to effectively conduct self-care activities.
Evidence suggests that, at least in the short run, self-
care behaviour can be modified through self-management
interventions [11]. However, it is important that interven-
tions aimed at supporting patients to cope with diabetes
and potentially co-occurring conditions (1) are person-
centred (not disease-centred), comprehensive and embed-
ded in the process of primary care within the health-care
system and (2) take into account and mobilize community
resources.
Although structured disease management programs
(DMPs) are embedded in routine primary care for patients
with type 2 diabetes in Germany [12], their ‘disease-centred’
design does not sufficiently take into account the chal-
lenge of comorbidity. For care management programs,
positive effects on quality of care and patients’ quality of
life have been reported. Still, though, the effect of care
management interventions on health-care utilization and
costs remains heterogeneous [7]. This finding is reinforcedby a recent systematic review of complex interventions
designed to improve outcomes in patients with multi-
morbidity (including comorbidity) in primary care and
community settings [13]. The review concludes that there
is limited evidence on the care of patients with multi-
morbidity, despite the prevalence of multi-morbidity and
its impact on patients and health-care systems [13].
Few researchers have assessed the effects on patient-
reported outcomes (PROs), such as self-care behaviour,
self-efficacy, attitudes, health service utilization, quality of
life and/or psychological indicators [14,15]. There are also
few trials in which the investigators reported ‘patient-
important’ outcomes related to death, morbidity (inclu-
ding hypoglycaemic events) and quality of life [16].
Care management interventions in the German health-
care system have been evaluated, with researchers re-
porting promising results for patients with osteoarthritis
[17], depression [18], chronic heart failure (CHF) [19] and
multi-morbidities [6]. However, further studies are ne-
cessary to explore the full potential of care manage-
ment interventions to improve outpatient diabetes care in
Germany in the context of multi-morbidity. Care manage-
ment is particularly challenging for small primary care
practices (PCPs) to deliver. Primary care practice network
(PCPnetwork)–based approaches might be a solution in
this context, because they allow provision of intensified
care from several practices, thus reducing the workload of
smaller PCPs. These approaches in turn entail challenges
regarding the flow of information between care managers,
PCPs and other sectors in the delivery of relevant health-
care services according to individual patients’ needs.
We have developed a complex PCPnetwork-based,
health care assistant (HCA)–led, information technology
(IT)–supported care management intervention based on
an existing pilot project. It involves integrated telephone
monitoring to improve diabetes care for patients with type
2 diabetes mellitus and multiple comorbidities. The study
protocol of our trial includes documentation of the eva-
luation methods to be deployed during the ‘evaluation
stage’ [20] of the complex intervention.
Methods/Design
Primary objective
Our primary objective in this study is to assess the
efficacy of a PCPnetwork-based, HCA-led, IT-supported
care management intervention with integrated telephone
monitoring for the improvement of self-care behaviour
among patients with type 2 diabetes mellitus and two or
more comorbidities. We aim to determine if there is a
difference in changes in diabetes-related self-care beha-
viour after 9 months (T1) of intensified care manage-
ment (as an add-on to usual care) compared to baseline
(T0) between the intervention group, which will receive
the Pathways to Change (PTC) intervention, and the
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ceive usual care only (Figure 1).
Secondary objectives
We further aim to compare the groups (PTC vs. TAU)
in the following aspects:
1. Change in diabetes-related self-care behaviour
compared to T0 after an 18-month period (T2) with
reduced intensity of care management and enhanced
by SMBG, with reduced intensity referring to longer
time lags between telephone monitoring contacts
(Figure 1).
2. Change in diabetes-related self-care behaviour after
9 months (T1)/18 months (T2) compared to T0,
adjusted for behaviour at baseline and other
important factors reported in the literature
(sex, age, marital status/domestic partnership,
social status, migration status, type of comorbidity,
perceived quality of health care, alcohol abuse and
diabetes-related emotional distress).
3. Changes in each dimension of diabetes-related
self-care behaviour (diet, exercise, SMBG, foot care
and smoking) at T1/T2 compared to T0.
4. Differences in change of glycosylated haemoglobin
A1c (HbA1c, %) at T1/T2 compared to T0 in the
subgroup of patients with a HbA1c T0 value >7.5%
(adjusted for the T0 HbA1c value).
5. Differences in the cumulative incidence of (severe)
symptomatic hypoglycaemia at T1/T2 compared to
T0 among those patients at risk for this event during
the respective observation period.
6. Differences in change of health-related quality of life
(HRQL) and self-efficacy at T1/T2 compared to T0
7. The distribution of potential health gains (that is,
improvements in self-care behaviour, HbA1c
percentage and HRQL) at T1 across socioeconomic
groups to assess whether the intervention is
equitable.
8. Differences at T1/T2 related to service utilization,
direct and indirect costs of health-care provision
during observation time (The financial family burden
of informal care provided by patients’ relatives is
particularly regarded within indirect costs).
9. The cost-effectiveness of the primary endpoint
(change in self-care behaviour at T1).
Study design
The study is designed as a prospective, 18-month, multi-
centre, two-arm, open-label, individual-level, randomized
parallel-group superiority trial (RCT). Eligible participants
will be randomly selected from among the aggregate pa-
tient population of 30 study centres (PCPs), and they will
be asked for their consent to take part in the study.Participating patients will be given a pseudonym by the
recruiting physician and only the pseudonym will be
reported to the study central office (the Department of
General Practice and Health Services Research, University
Hospital Heidelberg (AMV)), where the patients will be
centrally randomized on an individual level by a clinical
monitor, who will act as the sole randomization authority.
This person, who will not be involved in the care of the
trial patients or analysis of data, will be responsible for
allocation to the control arm (TAU) and the intervention
arm (PTC) according to a predefined randomization sche-
dule. As illustrated in Figure 1, the intervention will be
provided in addition to usual care. Blinding of either
patients or practice teams is not possible, owing to the
character of the intervention. The T0 assessment of pri-
mary and secondary outcomes will be conducted prior to
allocation of patients and after allocation at 9 months
(primary endpoint: T1) and at 18 months (follow-up: T2)
(Figure 1). Both the intervention and control groups will
receive usual care. Usual care will consist of diabetes care
within the scope of the German disease management pro-
gram for type 2 diabetes mellitus, DMP Diabetes. Care
provided for high-prevalence chronic comorbidities such
as chronic obstructive lung disease COLD, heart failure
and coronary heart disease (CHD) will also be organized
within the scope of DMPs on a voluntary basis in the
German statutory health insurance system [13]. Care pro-
vided for other diseases (chronic or acute) will be managed
by PCP physicians individually based on personal expe-
rience, guidelines and/or patients’ preferences.
Inclusion and exclusion criteria
Primary care practices
To function as a study centre, physicians based at PCPs
must fulfil the following criteria: They must be specialized
in general practice or internal medicine or as ‘medical
practitioners’ (praktischer Arzt) and must function as
‘primary care physicians’ (Hausarzt) according to German
regulations. Both group practices (Gemeinschaftspraxen)
and individual practices are eligible to participate. Inclu-
sion criteria for PCPs will be captured with a brief, indivi-
dualized questionnaire. PCPs that do not fulfil the
inclusion criteria will be excluded.
Patients
To be eligible for participation in the study, patients must
be 18 years of age or older, diagnosed with type 2 diabetes
mellitus (International Classification of Diseases, Tenth
Revision (ICD-10), codes E11 to E14) and enrolled in the
DMP Diabetes program. Furthermore, they must be diag-
nosed with at least two ‘severe chronic comorbidities’ ac-
cording to the definitions enshrined in German legislation
[22]. These comorbidities include, but are not limited to,
atherosclerosis (ICD-10 code I70), chronic coronary heart
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Figure 1 Graphical illustration of the elements and the timeline of the GEDIMAplus trial. Adapted from Perera et al. [21].
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http://www.trialsjournal.com/content/15/1/243disease (ICD-10 code I25), chronic obstructive lung dis-
ease (ICD-10 code J44), asthma (ICD-10 code J45), cere-
brovascular diseases (ICD-10 codes I60 to I69), depression
(ICD-10 codes F32 and F33), heart failure (ICD-10 code
I50), Parkinson disease (ICD-10 code G20) and/or chronic
pain (ICD-10 code R52). Additionally, written informed
consent is a prerequisite for participation in the study.
Patients who do not fulfil the inclusion criteria will be
excluded. Additional exclusion criteria are severe acute
psychiatric disorders (for example, schizophrenia, schizo-
typal and delusional disorders (ICD-10 codes F20 to F29));
dementia (ICD-10 codes F00 to F03); mental and be-
havioural disorders due to psychoactive substance use
(ICD-10 codes F11 to F16, F18 and F19), except for alcohol
(ICD-10 code F10) and tobacco use (ICD-10 code F17);
malignant neoplasms (ICD-10 codes C00 to C97) and/or
current chemotherapy or radiotherapy; transplanted organTable 1 Overview of outcome parameters, co-variables and in
Outcome parameters Measurement instruments
Primary outcome
Diabetes self-care Summary of Diabetes Self-Care
Measure–German version (SDSC
Secondary outcomes
Glycosylated haemoglobin A1c Patient chart
(Severe) symptomatic hypoglycaemia Patient chart/self-developed ite
Health-related quality of life EuroQol (EQ-5D)
Chronic disease–related self-efficacy Self-efficacy scale (SES6G)
Health-care utilization and costs Client Socio-Demographic and
Receipt Inventory (CSSRI)
Costs of informal care provided by
designated family member
Financial family burden (FFB)
questionnaire
Covariables
Type of diabetes therapy Patient chart
Comorbidities Patient chart
Medication Patient chart
Perceived quality of care PACIC-S
Emotional distress PAID Short
Depression WHO-5
Alcohol consumption AUDIT-C (German version)
Migration status Recommended ‘basic set of ind
for mapping migrant status’ in
Sociodemographic data (sex, age, housing,
partnerships, education, occupation,
equalized household income)
Sociodemographic Standards o
Federal Department of Statistics
(partially adapted)
Subjective social status One-item standardized measure
aAUDIT-C, Alcohol Use Disorders Identification Test; FQ, Family member questionna
PAID Short, Problem Areas in Diabetes scale (short version); PhysQ, physician-report
questionnaire/patient-reported measure; SES6G, Self-Efficacy for Managing Chronic
Organization (Five) Well-Being Index.and/or tissue status (ICD-10 code Z94); care involving
dialysis (ICD-10 code Z49); insurmountable language and
communication problems; and emergent cases.
Patients’ informal caregivers
One of the secondary research objectives is to assess the
costs of informal care in both study groups (PTC vs.
TAU). This information will be collected with the financial
family burden (FFB) questionnaire (Table 1), which ad-
dresses one family member who provides the most care
for the patient with type 2 diabetes. A caregiving family
member is defined as the family member who (1) from the
patient’s perspective, spends the most amount of time pro-
viding informal care (for example, a spouse, partner,
father, mother, son, daughter or others) and (2) lives in the
same household as the patient. It is important to note that
it is up to the individual patients to identify, from amongstruments of the GEDIMAplus triala
Data sources References
Activities
A-G)
PQ [9] (our own translation, unpublished)
PhysQ –
ms PhysQ –
PQ [23]
PQ [24]
Service PQ [25]
FQ [26]
PhysQ –
PhysQ –
PhysQ
PQ [27]
PQ [28]
PQ Psychiatric Research Unit, WHO Collaborating
Centre for Mental Health, Frederiksborg
General Hospital [29]
PQ [30]
icators
Germany
PQ [31]
f the PQ Federal Office for Statistics [32]
PQ German General Social Survey (ALLBUS) [33]
ire; PACIC-S, 11-item Patient Assessment of Chronic Illness Care short form;
ed measure captured by physician questionnaire/chart review; PQ: Patient
Disease 6-item Scale, German version; WHO-5, 5-item World Health
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the most care. As such, this construct explicitly considers
patients’ views and does not apply to an external defini-
tion. One informal caregiver per patient will be recruited.
Recruitment
Study centres
This multicentre RCT will be conducted in 30 PCPs that
formerly participated in a pilot study. PCPs were invited
to participate in the study by sending an official letter
from the study central office and requested their written
consent for participation.
Patients
The 30 PCPs will receive from the study central
office (through the intervention coordination centre,
Genossenschaft Gesundheitsprojekt Mannheim (GGM)) a
list of the inclusion and exclusion criteria for patients,
along with a screening list with random numbers. PCPs
will be asked to create a list of all potentially eligible
patients, based on the inclusion and exclusion criteria,
who are registered in their practice’s electronic database.
In a next step, the PCPs will select 40 patients from
among those on the list according to the sequence of
random numbers. Randomly selected patients will be con-
tacted and asked by the PCP physician whether they wish
to participate in the study. Patients who are not willing to
participate will be asked to give a reason for their decision
(on a voluntary basis). The number of patients ‘screened’,
‘asked’ and ‘asked and not included’, as well as the reasons
for exclusion or nonparticipation, will be documented by
the PCP physician and reported to the study central office.
This procedure will be repeated until a total of 20 patients
per PCP are recruited. Patients who are willing to partici-
pate will be informed by the PCP physician about the
aims, content, privacy issues and risks related to study
participation. Patients who provide their informed consent
to participate in the study will undergo a clinical examin-
ation and receive the patient questionnaires used to
capture the PROs.
Patients’ informal caregivers
Patients who give their informed consent to participate
in the study will be asked to hand over (on a voluntary
basis) an information leaflet, an informed consent form
and a questionnaire in a closed envelope to the family
member who provides them with the most care. The
participation of the ‘chosen’ family member is completely
voluntary and independent from the participation of the
patient who ‘chooses’ the family member.
Randomization
Patients will be randomly allocated to care management
(PTC) or usual care (TAU) at the individual level at a ratioof 1:1 stratified by (1) type of medical treatment (insulin
vs. oral medication or no medication) of their index
disease (type 2 diabetes) and (2) study centre (PCP). We
previously identified the type of medical treatment as the
strongest predictor of diabetes self-care in an unpublished
scoping review and will thus capture this variable by a
physician-reported questionnaire to serve as a validated
stratification criterion. We will hence perform stratified
block randomization with variable block lengths to ensure
study groups of approximately equal size. In order to
ensure concealment, the block sizes will not be disclosed.
Instead, this specific information will be provided in a
separate document with access restricted to the rando-
mization authority only. The randomization procedure is
closely linked to the data collection procedure insofar as
that it will be performed centrally using the ICW Care
Manager platform (InterComponentWare AG, Walldorf,
Germany). All eligible patients participating in the study
will be registered in this database, along with the phy-
sician-reported information about eligibility criteria and
type of medical treatment of diabetes, during a 3-month
recruitment period. ICW Care Manager contains virtual
folders for the two groups (PTC and TAU) within each
participating PCP. A randomization authority (that is, a
designated person not involved in care of the trial patients
and analysis of data) will access the database of registered
patients in weekly intervals to monitor the recruitment
process. Recruited and registered patients who fulfil the
inclusion criteria will be centrally randomized (stratified
by type of medical therapy and PCP) to the PTC or TAU
arm using a computerized random number generator to
create randomization lists for each stratum. The allocation
will be documented separately in an Excel file (Microsoft,
Redmond, WA, USA) with restricted access, except for
the randomization authority. Patient allocation to either
the intervention or control group will remain completely
concealed until data collection related to primary and sec-
ondary outcomes at T0 is completed. After baseline data
collection is completed, PCPs will be informed about the
allocation of their patients (identified by unique study
identification number) in an official letter from the inter-
vention coordinating centre (GGM), which in turn will re-
ceive the information from the study coordinating centre
(AMV).
Intervention
The intervention is a complex care management program
[34] aimed at improving diabetes self-care behaviour
among patients with type 2 diabetes and multiple co-
morbidities. The development of the multifaceted inter-
vention (Figure 1) is based on (1) a 12-month pilot study
(Gesundheitsbegleitung Diabetes Mannheim (GEDIMA))
conducted by the coordinating centre (GGM), including
171 patients; (2) focus groups with PCP physicians and
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the active engagement of local patient self-help groups in
formulating assessment contents and identifying com-
munity resources. The complex intervention will be deli-
vered as an add-on to treatment as usual and will consist
of three main elements: assessments, symptom and needs
monitoring and digital structured blood glucose testing.
Assessments
At the beginning of the study, patients in the PTC group
will undergo an IT-based assessment of medical and non-
medical needs and resources, which employs a structured
protocol, administered by a PCPnetwork-based HCA who
functions as the PCPnetwork case manager (NCM). The
NCM is authorized to access the ICW Care Manager
database with a unique password and username. At the
beginning of the study, the NCM will have access to only
anonymized data of those patients who are recruited into
the intervention arm and are based at the PCP at which
the NCM is in charge. The NCM will contact the PCPs in
order to de-pseudonymize ‘her’ patients and to deliver the
assessment. Note that the assessment results will not be
used as efficacy outcomes of the intervention, but rather
will be used solely for the purpose of delivering the inter-
vention itself.
The contents of the assessment are demographics (age,
sex, insurance status, living environment, education, mi-
gration status and/or cultural background), utilization of
existing health and social services related to individual
needs (participation in DMPs beyond DMP Diabetes,
hospitalization in the previous 12 months, social services,
home nursing services, medical aids, physiotherapy, podia-
trist, psychotherapy, selected symptoms and/or clinical
manifestations (thirst, lack of appetite, nausea, vomiting,
dyspnoea, fatigue, wounds, disorientation), biomedical pa-
rameters (blood pressure, weight, height, blood sugar),
SMBG, participation in diabetes education programs,
problems in organization of care and social situation, trip-
ping hazards and social resources (external caregivers,
family, neighbourhood).
In addition, the NCM will perform the following
standardized clinical assessments to identify entry points
for individual support: Mini-Mental Status-Test, Lawton
Instrumental Activities of Daily Living Scale (German
version), tandem stand, depression (5-item World Health
Organization (Five) Well-Being Index, German version)
[29], mobility and/or physical activity, alcohol use (Alcohol
Use Disorders Identification Test, German version) [30]
and tobacco use (in pack-years). The ICW Care Manager
platform provides the NCM access to physician-reported
background information related to patient diagnoses, medi-
cations, HbA1c, proteinuria and potentially existing patient
decrees (for example, living will, health-care proxy (‘Vorsor-
gevollmacht’), legal guardian (‘Betreuungsverfügung’)).The results of the initial assessment will be reported to a
so-called dialogue assistant (DA) based at the PCP, who in
turn will relay this information to the primary care phy-
sician in charge of the patient’s medical care. The assess-
ment results will serve as the basis for setting common
goals between the patient and his or her primary care
physician, which will be based on the patient’s needs. The
assessment results will be digitally stored on a secured ser-
ver for later use by the NCM during follow-up home visits
(FUPHV) and during the telephone monitoring. FUPHVs
will occur 6 months (FUPHV1) and 12 months (FUPHV2)
after study entry for patients in the PTC group (Figure 1).
Individualized assessments (including repeated reassess-
ments) of medical and nonmedical needs by non-phy-
sician health-care workers have previously been reported
to be an important element in attempts to improve
diabetes-related outcomes such as HbA1c level, weight
and body mass index, lipids, blood pressure, health-care
service use and physical activity [34]. Further elements
leading to improved outcomes are the use of decision-
making algorithms by health-care providers and a focus
on behaviour-related tasks [34], both of which are incor-
porated in the IT-supported assessment tool that will be
deployed in this intervention. The focus on both medical
and nonmedical needs ensures that the intervention is
person-centred (not disease-centred) and thus congruous
with evidence on how to improve diabetes care [14]. This
type of assessment of patients’ needs is an outreach elem-
ent which ensures that needs are assessed comprehen-
sively and takes into account the individual patient’s social
environment. The assessment is embedded in the process
of primary care within the health-care system and mo-
bilizes community resources to meet patients’ identified
medical and nonmedical needs. By using this approach,
we aim to reduce barriers to patients’ accessing support
systems and medical and/or nonmedical services based in
their local communities in order to improve management
of their disease. There is evidence that the combination of
these features is effective in improving diabetes care [14].
Symptom and needs monitoring
NCMs will engage in regular telephone monitoring
using a structured list of questions. The content and fre-
quency of the monitoring will be fixed, but the PCP and
NCM may decide that additional items should be incor-
porated. The NCM will deliver at least a total of 24 tele-
phone monitoring sessions according to a fixed schedule
(every 2 weeks for a period of 6 months, then monthly
for the rest of the intervention period for patients in the
PCT group) (Figure 1). The items monitored will be new
diagnoses; dyspnoea; incidence, frequency and severity
of hypoglycaemia; blood pressure; weight; fatigue; me-
dical and social problems; and follow-up on previously
mentioned problems and hospitalizations since the last
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of experiences of GGM in prior studies (GEDIMA study,
unpublished). The patient’s responses will constitute ‘red
flags’ according to the urgency of the symptoms and
signs. ‘Red flag’ answers require immediate contact with
the PCP for discussion and to take steps to address
them.
Evidence suggests that such high-intensity interventions
(more than ten contacts) delivered for 6 months or longer
are necessary in order to improve and sustain any change
in self-care behaviour [35]. Application of this element in
care management interventions in the German health-
care context has been shown to be effective in the early
diagnosis and treatment of acute complications and pro-
blems thereby reduce avoidable hospitalizations of chro-
nically ill patients [6]. This monitoring will also be used as
a feedback method related to patients’ control of their
disease or behaviours, the results of which will be impor-
tant in reinforcing positive behavioural change.
Digital structured blood glucose testing
Digital structured SMBG (using the ACCU-CHEK Smart
Pix device reader and the ACCU-CHEK 360° View tool
(Roche Diagnostics, Mannheim, Germany)) will be em-
ployed for symptom monitoring at 3-month intervals
(a total of three times) (Figure 1). The NCM will collect
the individual blood sugar profiles, transfer them into the
ICW Care Manager database and report the profiles to
the PCP in charge of the respective patient. The blood
sugar profiles will serve as a basis for telephone coaching.
SMBG is an essential self-care element among patients
with insulin-treated type 2 diabetes. However, for non-
insulin-treated patients with diabetes, a synthesis of the
existing evidence published by the German Institute for
Quality and Efficiency in Health Care (IQWiG) revealed
no evidence that SMBG improves diabetes-related out-
comes [36]. As noted in the IQWiG report, though, this
conclusion needs to be interpreted in light of scarce
data, especially in terms of potential effects on the inci-
dence of severe hypoglycaemia in non-insulin-treated
patients [35]. The authors of a recent systematic review
published by the Cochrane Collaboration, which in-
cluded 12 RCTs (duration range from 6 to 12 months),
wrote in their conclusion,
[W]hen diabetes duration is over one year, the
overall effect of self-monitoring of blood glucose on
glycaemic control in patients with type 2 diabetes who
are not using insulin is small up to six months after
initiation and subsides after 12 months. Furthermore,
based on a best-evidence synthesis, there is no
evidence that SMBG affects patient satisfaction,
general well-being or general health-related quality of
life. More research is needed to explore thepsychological impact of SMBG and its impact on
diabetes specific quality of life and well-being,
as well as the impact of SMBG on hypoglycaemia
and diabetic complications [36], abstract conclusions
section.
The use of self-monitoring by patients with non-insulin-
treated diabetes is controversial because reported esti-
mates of benefit regarding reductions in HbA1c levels
have varied in different systematic reviews [37]. A meta-
analysis in which the researchers studied individual patient
data also did not provide convincing evidence to support
the routine use of self-monitoring of blood glucose by
non-insulin-treated patients with type 2 diabetes [37]. The
‘scarce data argument’ and the potential effects of self-
monitoring on the incidence of severe hypoglycaemia are
the main rationale for including this element after T1 in
the intervention for non-insulin-treated patients with type
2 diabetes. As such, contamination of primary endpoint
effects due to participants’ use of the Smart Pix device
reader will be avoided. Instead, by means of a secondary
descriptive analysis, we hope that the study will add to the
existing body of evidence regarding self-monitoring by
non-insulin-treated patients with diabetes.
Composition and training of care management teams
The care management teams consist of 11 NCMs, 30 pri-
mary care physicians and 30 DAs based at each PCP. The
task of the DA is to facilitate communication between
NCMs, primary care physicians and patients. Each NCM
will care for about 26 patients at about three PCPs. Some
NCMs have previously participated in care management
interventions related to diabetes and CHD (GEDIMA and
Psychosocial Well-being and Disease Symptoms Health
for Patients with Multi-morbid Coronary Heart Disease
Patients (KHK-ProMA)) (n = 3); some have previously
participated in care management interventions related to
CHD alone (KHK-ProMA) (n = 2); and some have had no
experience with care management programs (n = 6). One
NCM is a native Turkish speaker who is specialized in the
provision of diabetes education. This NCM will be respon-
sible for delivering the care management intervention to
patients with a Turkish background to overcome language
barriers and appropriately address cultural preferences.
We thereby aim to address the special needs of this social
group, which constitutes about 22% of the population of
Mannheim (as of 30 December 30), where the majority of
study centres (PCPs) will be based. Potential language-
related barriers to data collection will be countered by
means of using a Turkish version of the patient question-
naire with this subgroup of participants.
Prior to the beginning of the intervention, all NCMs
will be trained using a team-based curriculum. The cur-
riculum was developed on the basis of experiences in
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representatives of local patient self-help groups. Com-
pletion of a 32-hour team-based training course is
mandatory for participating HCAs to function as NCMs.
Control
In the control group (TAU), practice teams will continue
to provide standard care in the context of the PCP-
centred care contract. This will involve gatekeeping for
enrolled patients as well as regular training based on
evidence-based guidelines through structured feedback in
peer review groups. As population-based DMPs for dia-
betes and other selected chronic diseases are part of rou-
tine care in Germany, patients may voluntarily participate
in these disease-specific DMPs. German DMPs consist of
regular follow-up visits every 3 months or less. They
include, on a regular basis and according to acute
needs, clinical examinations, laboratory tests (for example,
HbA1c tests), patient education and referrals to specialists
(for example, ophthalmologists, cardiologists, nephrolo-
gists, neurologists) [12]. However, essential elements of
care management interventions such as individualized as-
sessment, care planning (including nonmedical aspects),
home visits and frequent (symptom) monitoring are not
routinely part of DMPs [6].
Fidelity to the study protocol and variability between
sites and care management teams
The intervention seeks to ensure fidelity to the study
protocol with regard to adherence to the elements of the
intervention and the timeline (Figure 1). The IT-supported
delivery of the intervention allows assessment of fidelity to
the main intervention elements for all participants in the
intervention group. However, the intervention is explicitly
designed to allow adaptations to local contexts and
individual patients’ needs, preferences and cultural back-
grounds with regard to the consequences of structured as-
sessment and telephone monitoring. Adaptations to local
contexts and individual preferences (for example, diffe-
rential use of community resources and services) will be
documented in the ICW Care Manager database by the
NCM during her routine contacts. Figure 1 illustrates all
elements and the timeline of the intervention.
Data collection
AMV is responsible for administration, coordination, data
management and monitoring (including database setup
and validation, data entry, coding and query management).
The intervention coordinating centre (GGM) will carry
joint responsibility for administration, validation and data
entry. Each patient will be asked by the recruiting phys-
ician to fill in a pseudonymized, paper-based questionnaire
and hand it back to the recruiting physician in a closedenvelope. This patient questionnaire will be used to cap-
ture the PROs analysed in this study.
Primary care physicians will document additional data
from each patient’s charts by completing a paper-based
questionnaire (including inclusion and exclusion criteria,
diagnoses, medications, hospitalizations and hypoglycae-
mia prior to recruitment) and assessing the patient’s cli-
nical status (for example, blood pressure, blood glucose,
latest HbA1c value). The physician questionnaire will not
contain any data that allows identification of the patient.
The patient questionnaire and physician-reported chart
review will be performed at T0, T1 and T2. In addition, in
order to capture the cost of informal care for the health-
care economic evaluation, patients will be asked to hand
over the FFB questionnaire (in a closed envelope along
with additional background information) to their relative
who provides them with the most care for their diabetes.
Data collected from the patient’s informal caregiver will be
anonymized in a way that will allow linking the informal
care burden with the disease severity of the respective pa-
tient. The collected data will be directed to the study cen-
tral office (AMV) through the following channels:
1. Physician-reported chart reviews and patient ques-
tionnaires will be sent by the PCPs in paper-based for-
mat to the study coordination centre (GGM) by mail. At
GGM, an authorized employee will enter the chart
review data into the ICW Care Manager database and
thereby register participating patients by study identifi-
cation number. All data entered into the ICW Manager
database will be transferred (encrypted via the internet)
to the Centre for Information and Medical Technologies
(Zentrum für Informations und Medizintechnologie
(ZIM)) at the University Hospital Heidelberg and stored
on a secured server. Authorized clinical monitors based
at AMV can access the stored data in ‘real time’ to check
conformity with inclusion criteria and monitor the pro-
gress of the recruitment process. Validation of entered
data will be carried out by built-in checks in the ICW
Care Manager and by clinical monitors.
2. The paper-based patient questionnaires containing
the chart reviews and PROs will be stored at the GGM
office and sent to the study central office (AMV) at
regular intervals.
3. The FFB questionnaire designed for patients’ rela-
tives will be sent directly to AMV by patients’ relatives
in enclosed, post-paid envelopes. The written consent
forms for patients’ relatives will be returned to GGM.
Patient questionnaires and FFB questionnaires will be
scanned and digitally stored on a secured server at
AMV.
Monitoring
A risk-adapted strategy will be employed to ensure ad-
herence to the portion of the study protocol dedicated
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rized employees at the study central office (AMV) will
conduct practice visits at 10% of PCPs randomly selected
from among the pool of participating PCPs during the
first 3 months of the intervention. These monitoring
visits will include (1) an inspection of informed consents
of all patients recruited by the PCP and (2) a review of
the charts of 10% of patients recruited by the PCP to
check if documented items and source data are congru-
ent and that they are being recorded in conformity with
the study protocol. A detailed monitoring manual will
be developed by the study central office prior to the be-
ginning of the intervention. Depending on the results of
these visits, further quality assurance measures may be
defined by the study central office (AMV) and the inter-
vention coordinating centre (GGM).
Outcome measures
Primary outcome
The intervention is aimed primarily at improving ‘self-care’
as a multidimensional construct consisting of the following
five dimensions: diet, exercise, SMBG, foot care and smo-
king behaviour. This primary outcome is a PRO and will
be operationalized by the German version of the revised
Summary of Diabetes Self-Care Activities (SDSCA-G) [9].
The English version of the revised SDSCA is a widely used,
appropriate [38], valid and reliable tool with moderate
test–retest reliability [9] for capturing self-care behaviour.
The SDSCA-G is based on a structured forward–back-
ward translation of the original English instrument. The
SDSCA-G consists of 11 items and will be employed as
part of the paper-based questionnaire. The response op-
tions for SDSCA-G items 1 to 10 (excluding smoking) are
‘days per week’ (on a scale of 0 to 7) on which the patient
performed particular self-care tasks [38]. For each group
of items (for example, diet), a mean number of days is cal-
culated. The SDSCA-G scale is used as a continuous
measure to determine if there has been improvement
compared to baseline at subsequent time points. As a re-
sult of strong ceiling effects, the ‘medication’ item is not
included in the most recent recommended version the in-
strument [9].
No score cutoff point on the SDSCA has been de-
termined to discriminate between adherence and non-
adherence [38], and no minimal clinically relevant change
in SDSCA ‘scores’ has yet been formulated [39]. This
means that, in order to determine a minimal clinically
relevant change for this study, the research team will need
to draw upon (1) published data on the degree of change
in SDSCA values reported in interventions designed to
improve self-management and (2) estimates of ‘realistic’
changes that the intervention can bring about.
The primary outcome that will be used to assess the
efficacy of the intervention is the difference in meanchange in SDSCA-G ‘score’ on items 1 to 10 (excluding
smoking) per patient compared to T0) after 9 months of
the intervention (T1) between both groups (PTC vs.
TAU), determined on the basis of patients’ self-reports
(Table 1).
Secondary outcomes
To address the secondary objectives of the study, we will
attempt to capture the following secondary outcomes
(Table 1):
1. The mean change in SDSCA-G ‘score’ on items 1
to 10 (excluding smoking) for each group (PTC vs.
TAU) will be compared to T0 after 18 months
of the intervention T2 to assess sustainability of
effects with reduced intensity of care management
and enhanced by SMBG.
2. The mean change in each of the five dimensions of
self-care captured using the SDSCA-G instrument
will be compared to T0 for each group (PTC vs.
TAU) at T1 and T2 of the intervention to assess the
influence of the intervention on specific self-care
behaviours.
3. The mean change in physician-reported HbA1c (%)
at T1 and T2 will be compared to T0 among the
subgroup of patients with a T0 value of HbA1c less
than 7.5%. A 10% improvement from the T0 value
[39] at 9 months and 18 months will be regarded as
a clinically relevant change.
4. The cumulative incidence of physician-reported
(severe) symptomatic hypoglycaemia at T1 and T2
among those patients at risk for this event during
the respective observation period will be evaluated.
Symptomatic hypoglycaemia refers to hypoglycaemia
with blood glucose less than 60 mg/dl, and ‘severe
symptomatic hypoglycaemia’ will be considered an
event of hypoglycaemia which necessitated external
support. Patients will be considered to be ‘at risk’
for (severe) symptomatic hypoglycaemia for the
subsequent time period if they receive oral
antidiabetic medication and/or insulin therapy
at T0 or T1.
5. The mean change in patient-reported HRQL
will be captured by using the EuroQol instrument
(EQ-5D) at T1 and T2 and compared to T0. EQ-5D
is a 5-item, simple preference–based index measure
which has frequently been applied to measure
HRQL in type 2 diabetes patients (including the
United Kingdom Prospective Diabetes Study).
A difference of 0.03 on overall EQ-5D index score
after 9 months and 18 months will be considered
clinically relevant [39].
6. The mean change in patient-reported self-efficacy
will be captured using the Self-Efficacy for Managing
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short and validated instrument [24].
7. The equity/efficacy ratio will be calculated as the
ratio between the change (compared to T0 at T1)
in SDSCA-G ‘score’ on items 1 to 10 (excluding
smoking), HbA1c (%) and EQ-5D index score
among the lowest vs. highest socioeconomic patient
subgroups (including education, occupation, income
and subjective social status) in both arms of the trial
(PTC and TAU). This includes subgroup analyses for
migrant populations.
8. Further secondary outcomes will be captured using
the Client Socio-demographic and Service Receipt
Inventory (CSSRI) [25] and the FFB questionnaire
[26]. Both instruments have been adapted to the
special needs of patients with type 2 diabetes and
were pretested before general application. CSSRI
provides data on all kinds of service utilization and
thus will be a crucial prerequisite to capturing
resource consumption. In addition to direct and
indirect costs, particular attention will be focused on
the financial burden of informal care. Together
with intervention costs, economic evaluations will
be analysed from a societal perspective.
Table 1 provides an overview of all instruments that
will be used in this study to capture primary and
secondary outcomes as well as relevant covariables.
Statistics
Sample size calculation
Sample size will be calculated based on the expected dif-
ference between the two treatment groups in mean change
in the SDSCA-G score from T0 compared to T1. On the
basis of data derived from published studies in which the
researchers used the revised SDSCA score as an outcome
measure [40-42], we estimate a mean change of 0.5 days
(standard deviation = 2.0) in the overall SDSCA-G ‘score’
(calculated as the sum of days of items 1 to 10 divided by
10) per patient in 9 months as the minimal clinically rele-
vant change. On the basis of these estimates, we will need
a total of 506 patients (253 per arm) to detect an effect
size (Cohen’s d) of 0.25 between groups (PTC vs. TAU)
(50% relative increase in self-care) with a power of 80% by
two-sided t-test of two independent samples at a signifi-
cance level of 5%. Assuming a dropout rate of 15% over
the period of 9 months, the overall sample size required is
a total of 582 participants (291 per arm).
Analysis plan
A detailed description of the statistical methods that we
will employ in this study will be provided in a statistical
analysis plan. Data analysis will be done blinded to treat-
ment arm allocation (that is, the treatments will beidentified as 1 and 2 until analysis is completed). The
primary analysis will be based on the 9-month follow-up
data (T1).Populations for analysis
The intention-to-treat (ITT) population will consist of
all randomized patients. Following the ITT principle, pa-
tients will be analysed in the treatment arms to which
they were originally randomized, regardless of whether
they refused or discontinued treatment or whether other
protocol deviations are known to have occurred. The
per-protocol (PP) population will consist of those ITT
patients with no major protocol violations. The criteria
for the exclusion of patients from the PP population will
be determined by the study team at the latest time point
before database lock.Statistical hypotheses, methods and analyses
The primary efficacy endpoint is the change in SDSCA-G
score from T0 to T1, that is, the difference in SDSCA-G
score from T1 to T0. The study objective will be statisti-
cally formulated as a test of the null hypothesis H0: μ1 = μ2
(mean difference in SDSCA-G scores between T1 and T0
in the two groups are equal) against the alternative hy-
pothesis H1: μ1 ≠ μ2 (mean difference in SDSCA-G scores
between T1 and T0 in the two groups are different). The
null hypothesis will be tested at the two-sided significance
level of α = 0.05.
In the primary efficacy analysis, we will use a multilevel
regression approach with patients at level 1 and NCMs at
level 2. The primary model will include treatment group
as a fixed factor, NCMs as a random factor and the base-
line value of SDSCA-G and type of medical treatment as
covariates. The results will be presented as the mean
between-group difference in SDSCA-G scores (T1 −T0)
with the corresponding 95% confidence interval. The asso-
ciated Cohen’s effect size d will be calculated. To support
the primary analysis, all potentially relevant baseline char-
acteristics will be added to the model as covariates in
sensitivity analyses. A further sensitivity analysis of the
primary endpoint will include an unadjusted two-sample
t-test of the change in SDSCA-G score from T0 to T1.
The results of these sensitivity analyses will serve to ex-
plain and interpret the results of the primary analysis. The
primary analysis will be performed in accordance with the
ITT principle. An additional sensitivity analysis will be
conducted on a per-protocol analysis set.
In the statistical analyses of the secondary endpoints
numbered 1 to 6 (see above), we will use the same multi-
level approach that we will use in the primary analysis. Ac-
cording to the scaling of the considered endpoint, a linear
or logistic two-level regression model will be fitted. The
results will be presented in an analogous manner to the
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the significance level of α = 0.05.
The equity/efficacy ratio [43] (and respective 95% con-
fidence interval) will be calculated as the ratio of effects
at T1 on health outcomes (change in SDSCA score,
HbA1c (%) and HRQL) between the highest and lowest
socioeconomic groups (related education, income, sub-
jective social status) for both groups (PTC and TAU)
compared to T0. Additional consideration of social
group sizes will be ensured by calculating the concentra-
tion index (PTC vs. TAU) and plotting concentration
curves at T0 and T1, respectively.
Subgroup analysis for nominal social groups will be
performed by means of interaction terms [44] for migra-
tion status (Turkish migrants, non-Turkish migrants,
participants without migration background) to be in-
cluded in the regression equations for respective health
outcomes at T1 (change in SDSCA score, HbA1c (%),
HRQL).
Statistical analyses related to secondary outcomes 8
and 9 (see above) will be focused on the incremental
cost-effectiveness ratio [45,46], which will be used to re-
late mean cost differences to mean differences in bene-
fits between the intervention and control groups. The
bootstrap method will be used to quantify statistical un-
certainty, and a net benefit approach will be applied
[47,48]. Maximum willingness to pay thresholds and
cost-effectiveness–acceptability curves [49,50] will be de-
termined. Sensitivity analyses will provide information
on robustness of assumptions.
Because no adjustments for multiple endpoints are
planned, the findings, especially those related to secon-
dary outcomes and subgroup analyses [44], will be inter-
preted with caution in view of the number of statistical
tests undertaken. Only the results of the primary efficacy
analysis will be interpreted in a confirmatory manner.
Confirmatory subgroup analyses are not planned. No in-
terim analysis with regard to efficacy will be done.
Missing data
In cases of missing data, multiple imputations will be
used to complete the data set for analysis. A complete
case analysis will be performed to assess the influence of
missing data and the value of adopting multiple imput-
ation methods.
Process evaluation
Data collected during NCM-led assessments and de-
livery of the intervention will be exported from the ICW
Care Manager in anonymized format to perform a
process evaluation. This evaluation will include data re-
lated to participation in DMPs, hospitalizations, use of
social services, existence of patient advance directives,
clinical parameters (blood pressure, body weight, height,blood sugar), use of podiatrists, use of psychotherapy,
participation in diabetes education, results of clinical as-
sessments and actions taken.
Ethics and legal aspects
The study is being conducted in accordance with medical
professional codex and the Helsinki Declaration (2013).
The study is also being carried out in accordance with the
German Federal Data Security Law (BDSG). All profes-
sionals participating in the study oblige to adhere to the
above-mentioned declarations and laws. Participation of
PCPs, patients and/or their relatives is voluntary. Consent
can be withdrawn at any time without any consequences
regarding patients’ (usual) care. All patients will be in-
formed about the aims, content, duration and process of
the trial, particularly with regard to risks and unintended
consequences, through written information brochures and
face-to-face communication with their PCP physicians.
Data will be collected and analysed pseudonymously for
patients, patients’ relatives, physicians and NCMs. Data
obtained from DAs will be anonymized. Pseudonyms will
be generated as follows. PCPs will be numbered 1 to 30,
and the key will remain in the intervention coordinating
centre (GGM). Patients recruited within each PCP will be
given a pseudonym consisting of a combination of the
PCP number and a running number (for example 3-15 for
patient 15 in PCP 3). The key will remain in the recruiting
PCP. Patients’ relatives will be given pseudonyms consist-
ing of the letter ‘R’ plus the associated patient’s pseudo-
nym (for example, R-3-15 for the relative of patient 15 in
PCP 3). No key will be generated for patients’ relatives.
NCMs will be numbered from 1 to 11. The key will
remain in the intervention coordinating centre (GGM).
Access to all keys will be forbidden for anyone except the
key holders.
Special emphasis in the information brochure will be
paid to the following privacy issue. During data entry of
physician chart reviews into the ICW Care Manager
database at T1 and T2, the authorized employee at
GGM will have access to electronic patient records data,
including full names, dates of birth and assessment re-
sults from the preceding time period since T0 for all pa-
tients in the intervention arm. This means that patients’
identity will not be concealed during data entry at T1
and T2. For the data analysis, however, all data will be
fully anonymized when exported by the authorized data
manager at the study central office (AMV). This privacy
issue will be handled as follows: (1) through the written
informed consent form, in which we explicitly mention
that the patient’s identity may be disclosed during data
entry at T1 and T2, and (2) through a written decla-
ration of confidentiality, which must be signed by the
authorized employee of GGM in order to qualify for data
entry.
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tent, duration and process of the trial, particularly with re-
gard to risks and unintended consequences, through
written information brochures. Written informed consent
will be obtained from patients’ relatives. Further privacy
issues are related to the hardware and software infrastruc-
ture that will be employed in this study within the scope
of the ICW Care Manager database. To address these is-
sues, the software will be used on a secured server at ZIM.
The system architecture for this project draws upon
four virtual servers: an application server and database
server for the production environment and an application
server and database server for the test environment. A
general proxy server will precede these servers to ensure
the security of data stored on the database server. Access
to the application-server via the internet will be necessary
for the NCM to conduct the intervention, and physician-
reported data entered at T0 to T2 by the GGM employee
will also be transferred via the internet. Both external
communication (proxy server with the internet) and in-
ternal communication (proxy server with the application
server) will be secured via HTTPS. The ICW Care
Manager system uses TLS 1.1 encryption to guard against
unauthorized access to protected health information
that is transmitted over an electronic communications
network.
Control of access to the application will be guaranteed
by person/entity authorization with a username and
password combination. Passwords will be salted with a
128-bit salt and hashed using a cryptographically strong
mechanism. Password complexity will be enforced by
the application according to the password complexity
configured by the customer. Control of access in the ap-
plication will be ensured by user administration, which
allows for the definition of roles and permission to
restrict functionality (read, write, create, update and
delete) on a graphical user interface (GUI) level and to
restrict access to data objects. Patient-level security is
guaranteed by restricting the visibility of patient identi-
fying information and all patient-related data to a user
or a group of users (for example, to guarantee that
NCMs have access only to digital records of ‘their’ pa-
tients in the intervention am, but not to the patient re-
cords of other NCMs or to the control group records).
Audit control will include a GUI-based audit feature
which allows a user with the relevant permissions (for
example, the authorized clinical monitor) to query an
audit log that contains entries of all relevant accesses to
the system with specification of the accessing user, date,
time, type, scope and accessed data object. Furthermore,
through technical file-based logging, the application
itself logs technical information in disk-based log files
that may contain relevant information such as system
startup, shutdown time stamps and import processes.The study protocol was approved by the ethics commit-
tee of the Medical Faculty of the University of Heidelberg
(S-590/2013) and by the ethics committee of the Medical
Association Baden-Württemberg (B-F-2014-007) prior to
the start of the study. The trial is registered with Current
Controlled Trials (ISRCTN 83908315).
Discussion
We hope that this study will contribute to current know-
ledge about the efficacy and feasibility of PCPnetwork-
based approaches to handling the complex health-care
needs of patients with type 2 diabetes and multiple co-
morbidities. Delivering person-centred, comprehensive
care while taking into account and mobilizing community
resources [14] is a challenging task for health-care sys-
tems. Care management interventions at the primary care
level in the German health-care system have previously
been evaluated, with promising results [6,17-19]. However,
care management has turned out to be particularly chal-
lenging to deliver for small PCPs. PCPnetwork-based ap-
proaches might be a solution in this context, because they
allow the provision of intensified care to patients by
several practices, thus reducing the workload of smaller
PCPs. Provided that the intervention proves to be effica-
cious, this care program could be disseminated through-
out PCP-centred care contracts.
Trial status
Recruitment of the study centres has been completed.
Recruitment of patients started on 1 February 2014 and
was completed in May 2014.
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